$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
乐伐替尼治疗放射性碘难治性甲状腺癌
2025-10-19 11:44:20
Check Details
甲状腺癌患者如何服用乐伐替尼?
2025-10-19 11:44:20
Check Details
乐伐替尼的3大适应症
2025-10-19 11:44:20
Check Details
乐伐替尼适用于分化型甲状腺癌患者的治疗
2025-10-19 11:44:20
Check Details
甲状腺癌靶向治疗药物仑伐替尼
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌是否安全有效?
2025-10-19 11:44:20
Check Details
乐伐替尼改善分化型甲状腺癌无进展生存时间
2025-10-19 11:44:20
Check Details
日本患者队列分析:乐伐替尼治疗碘难治性甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼+依维莫司增强抗肿瘤活性——靶向肿瘤生长和血管生成
2025-10-19 11:44:20
Check Details
分化型甲状腺癌的靶向药物乐伐替尼
2025-10-19 11:44:20
Check Details
乐伐替尼 vs安慰剂治疗放射性碘难治性甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌优于安慰剂
2025-10-19 11:44:20
Check Details
1
2
...
2438
2439
2440
2441
2442
2443
2444
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
7
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
8
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
9
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
10
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
11
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
12
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights